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Abstract
Introduction Evidence suggests that alterations in estrogen
signaling pathways, including estrogen receptor-α (ER-α),
occur during breast cancer development. A point mutation in
ER-α (nucleotide A908G), producing an amino acid change
from lysine to arginine at codon 303 (K303R) results in receptor
hypersensitivity to estrogen. This mutation was initially reported
in one-third of hyperplastic benign breast lesions, although
several recent studies failed to detect it in benign or malignant
breast tissues.
Methods We screened 653 microdissected, newly diagnosed
invasive breast tumors from patients in the Carolina Breast
Cancer Study, a population-based case-control study of breast
cancer in African American and white women in North Carolina,
for the presence of the ER-α A908G mutation by using single-
strand conformational polymorphism (SSCP) analysis and 33P-
cycle sequencing.
Results We detected the ER-α A908G mutation in 37 of 653
(5.7%) breast tumors. The absence of this mutation in germline
DNA confirmed it to be somatic. Three tumors exhibited only the
mutant G base at nucleotide 908 on sequencing, indicating that
the wild-type ER-α allele had been lost. The ER-α A908G
mutation was found more frequently in higher-grade breast
tumors (odds ratio (OR) 2.83; 95% confidence interval (CI)
1.09 to 7.34, grade II compared with grade I), and in mixed
lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12)
compared with ductal carcinomas, although the latter finding
was not statistically significant.
Conclusion This population-based study, the largest so far to
screen for the ER-α A908G mutation in breast cancer, confirms
the presence of the mutant in invasive breast tumors. The
mutation was associated with higher tumor grade and mixed
lobular/ductal breast tumor histology.
Introduction
The principal risk factors for breast cancer are hormonal or
reproductive factors that increase exposure to estrogen [1].
The importance of estrogen in breast cancer development is
further supported by studies demonstrating the occurrence of
marked changes in estrogen signaling and expression of the
two estrogen receptors (ERs) ER-α and ER-β during breast
tumorigenesis and progression [2-8]. Although mutations in
the ER-α gene are relatively rare in primary breast cancers
[2,3], Fuqua and colleagues recently described a point muta-
tion in ER-α in one-third of typical breast hyperplasias [9], and
also observed this mutation in a high percentage of breast
tumors [10]. This A→G base substitution at nucleotide 908 in
codon 303, referred to as ER-α A908G or K303R, results in
an amino acid change of lysine to arginine. The mutation
affects the border of the hinge and the hormone-binding
domains of ER-α and has been reported to confer hypersensi-
tivity to estrogen compared with wild-type ER-α, leading to
increased cellular proliferation at sub-physiologic levels of
estrogen [9]. No difference in estradiol affinity was detected
between the mutant and wild-type ER-α; however, the mutant
exhibited enhanced binding to the TIF-2 coactivator at low
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A908G or K303R mutation renders the receptor hypersensi-
tive to phosphorylation at Ser305 through the phosphatidyli-
nositol 3-kinase/Akt signaling cascade [11], protein kinase A
[12] and p21-activated kinase [10].
The enhanced function of the hypersensitive ER-α A908G
mutant and its discovery in early hyperplastic breast lesions
makes it a potentially important marker for studies of breast
cancer etiology and progression. In the present study, we
screened a series of newly diagnosed invasive breast tumors
from patients enrolled in the Carolina Breast Cancer Study
(CBCS), a population-based case-control study of breast can-
cer in African American and white women in North Carolina,
for the A908G point mutation in ER-α by using a combination
of single-strand conformational polymorphism (SSCP) analy-
sis and 33P-cycle DNA sequencing. Our results extend the ini-
tial observations of Fuqua and coworkers [9,10] by confirming
the presence of this mutation in some invasive breast
carcinomas.
Materials and methods
Study population
The CBCS is a population-based case-control study of breast
cancer. Participants include women, aged 20 to 74 years,
residing in 24 contiguous counties of central and eastern
North Carolina [13]. Women with a first diagnosis of invasive
breast cancer between 1993 and 1996 were identified by the
North Carolina Central Cancer Registry through a rapid case
ascertainment system. Women diagnosed before the age of
50 years and African American women were oversampled to
ensure that they comprised roughly half the study sample.
Additional details of the study design are described elsewhere
[13]. All aspects of this research were approved by the Univer-
sity of North Carolina (UNC) School of Medicine Institutional
Review Board. A total of 861 breast cancer cases were eligi-
ble for and consented to participate in the CBCS. Epidemio-
logic risk factor information was obtained from questionnaires
that were administered to participants in their homes by
trained nurse-interviewers. Clinical data and information on
tumor characteristics were obtained from medical records or
by a direct histopathologic review of tumor tissue. The ER sta-
tus of breast tumors was determined primarily through a
review of medical records (n = 567), and by immunohisto-
chemical staining in the remaining cases (n = 62) in the Tissue
Procurement and Analysis Facility at UNC as described previ-
ously [14].
Tumor tissue preparation and histopathologic 
evaluation
Formalin-fixed paraffin-embedded tumor blocks were obtained
from pathology departments at participating hospitals for 798
of the 861 breast cancer cases. Of these, 684 had sufficient
tumor tissue for molecular analyses. Tumors were sectioned
as described previously [15] and underwent standardized his-
topathologic review by the study pathologist (JG), which
included scoring of each tumor for histologic grade, nuclear
grade and mitotic index. These three features were considered
in assigning the Nottingham score (of 1 to 9), which was then
transformed to a three-level combined grade (grades 1 to 3).
With the hematoxylin/eosin-stained slide as a guide, the area
of tumor was microdissected away from other surrounding
non-tumor tissue, and DNA lysates were prepared for molecu-
lar analyses by using Proteinase K extraction.
Of the 684 tumors available for molecular studies, 653 were
successfully screened for mutations in a 104-bp region of
exon 4 surrounding codon 303 of ER-α, using a combination
of SSCP and 33P-cycle DNA sequencing. The tumors that
were screened for ER mutations were more likely to be of later
stage (P = 0.005), larger size (P = 0.0002), lymph node pos-
itive (P = 0.006), and higher combined grade (P = 0.04) than
those that were not screened, which is consistent with the
greater availability of tumor tissue from larger breast tumors.
However, the cases screened for mutations did not differ from
those that were not screened on age (P = 0.42), menopausal
status (P = 0.90), race (P = 0.63), ER status (P = 0.68), or
breast tumor histologic subtype (P = 0.48).
PCR amplification of ER-α exon 4
A 104-bp fragment of exon 4 surrounding codon 303 was
amplified with primers ER4A (5'-ATGAGAGCTGCCAAC-
CTT-3') and ER4BS (5'-AACAAGGCACTGACCATCT-3').
Reactions were performed in 1 × PCR buffer (50 mM KCl, 10
mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 0.001% gelatin), with
100 µM each of the four deoxyribonucleotide triphosphates,
1.25 units of AmpliTaq Gold DNA Polymerase (ABI), 0.6 µM
of each primer, and 1 µl DNA lysate under the following cycle
conditions: one cycle of 95°C for 8 min, 35 cycles of 95°C for
1 min, 60°C for 1 min and 72°C for 1 min, and a final extension
at 72°C for 10 min. Handling of all tissues and DNA and the
performance of initial PCR reactions were performed in a sep-
arate clean room to avoid contamination by PCR products.
SSCP screening
Mutations within the 104-bp region of ER-α exon 4 surround-
ing codon 303 were evaluated by SSCP analysis. First-round
PCR product was diluted in distilled H2O (about 1:25) and 1
µl was used in a 20 µl SSCP-PCR reaction containing each
primer ER4A and ER4BS at 600 nM, 1 × PCR buffer, each
dNTP at 150 µM (except 22.5 µM dCTP and 0.2 µl of α-
labeled 32P-dCTP (ICN)), and 0.5 unit of AmpliTaq Gold DNA
Polymerase (ABI). Cycling parameters were one cycle of 95°C
for 5 min, 60°C for 1 min and 72°C for 1 min, 33 cycles of
94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final
extension of 94°C for 1 min followed by 60°C for 10 min. The
SSCP-amplified PCR product was diluted 1:50 in 0.1% SDS
and 10 mM EDTA, mixed with 92% formamide and 40 mM
EDTA stop dye at a 1:1 ratio, denatured, and analyzed by
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acrylamide gel containing 1 × Tris/borate/EDTA buffer along
with positive, negative, and undenatured control samples.
Gels were run at 40 W at 4°C and transferred to chromatog-
raphy paper, dried, and then exposed to film (Hyperfilm MP) at
-80°C for 2 days. SSCP was repeated on at least 10% of
tumors that initially gave a wild-type SSCP result (n = 69), and
all of these tumors again showed only the wild-type SSCP
pattern.
33P-cycle sequencing
Tumor samples exhibiting abnormal band migration by SSCP
were sequenced on both the forward and reverse DNA
strands by using 33P-labeled cycle sequencing methods. The
PCR products were incubated at 37°C with ExoSAP-IT (USB)
(2 µl per 5 µl PCR product) for 15 min before sequencing.
Cycle sequencing was performed with the Thermo Sequenase
Radiolabeled Terminator Cycle Sequencing Kit (USB) in
accordance with the manufacturer's instructions, using either
primer ER4A or ER4BS for 30 cycles of 95°C for 30 s, 62°C
for 30 s, and 72°C for 1 min. Stop solution (95% formamide,
20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol
FF) was added and samples were heated to 70°C for 5 to 10
min before being run on an 8% polyacrylamide standard
sequencing gel. Gels were dried on chromatography paper
and then exposed to film (Hyperfilm MP). All mutations were
confirmed (and the possibility of mutation artifacts was ruled
out) by sequencing of a second, separately amplified PCR
product. Additionally, at least 5% of SSCP-negative tumors
were sequenced (n = 46), but no mutations were found in
these samples.
35S manual sequencing
The ER-α exon 4-amplified 104-bp PCR products were incu-
bated at 37°C with ExoSAP-IT (USB) (2 µl per 5 µl of PCR
product) for 15 min before asymmetric PCR. Asymmetric PCR
reactions were prepared to generate single-stranded DNA
products in both the forward and reverse directions. The for-
ward asymmetric PCR reaction consisted of 300 nM primer
ER4A and 6 nM primer ER4BS; the reverse reaction con-
tained 6 nM primer ER4A and 300 nM primer ER4BS. All other
reaction conditions were the same as described for first-round
PCR. The amplified single-stranded products were prepared
for sequencing by filtration through Centricon 30 spin filters
(Amicon). The products were sequenced with the Sequenase
2.0 dideoxy-termination method with the use of 35S-dATP to
reveal the bands. All mutations were confirmed by sequencing
in a separately amplified aliquot of DNA to rule out mutation
artifacts.
Automated fluorescent sequencing
Sequencing was conducted at the UNC DNA Sequencing
Core Facility on a 219-bp PCR product amplified from ER-α
exon 4 with primers ER5'#1 (5'-AACACAAGCGCCAGA-
GAG-3') and ER4B (5'-CTGAAGGGTCTGGTAGGA-3'). The
PCR product was purified by using ExoSAP-IT (USB; 2 µl per
5 µl of product), and was cycle sequenced with fluorescently
labeled Big Dye v1.1 terminators (ABI) on a 3730 DNA Ana-
lyzer (ABI) with a 48-capillary array. Foundation Data Collec-
tion v2 (ABI) software was used to collect and analyze the
sequencing data.
SNaPshot dideoxy primer extension assay
ER-α exon 4 PCR-amplified products were incubated at 37°C
with ExoSAP-IT (USB; 2 µl per 5 µl of PCR product) for 15 min
before mutation screening with SNaPshot (ABI). SNaPshot
was performed with a 1:10 (about 0.2 pM) dilution of the puri-
fied ER-α exon 4 PCR-amplified product with primers
ERSNP303-5' (5'-CGCTCATGATCAAACGCTCTAAGA-3')
at 1.0 µM final concentration and ERSNP303-3' (5'-AAG-
GCCAGGCTGTTC-3') at 2.0 µM final concentration in the
SNaPshot Multiplex Ready Reaction Mix (ABI) with the follow-
ing cycle conditions: 96°C for 20 s, 64°C for 10 s, 72°C for
30 s, for 25 cycles. The reactions were then treated with 1 unit
of shrimp alkaline phosphatase (Promega) and incubated for 1
hour at 37°C followed by deactivation at 75°C for 15 min. The
samples and SNaPshot controls were analyzed on the ABI
377 Genetic Analyzer with the GeneScan data analysis pro-
gram (ABI).
Positive control
A formalin-fixed paraffin-embedded non-study hyperplastic
benign breast tissue was confirmed by 33P and 35S sequenc-
ing to carry the ER-α A908G mutation and this sample was
used as a positive control throughout the screening studies.
This tissue also produced a prominent band shift on SSCP
and was positive for the mutation by SNaPshot. Mutant ER-α
exon 4 PCR product was cloned from this control sample and
several clones were sequenced for further confirmation of the
presence of the mutation in this tissue.
Statistical analysis
ER-α variants were evaluated for prevalence and type. Using
SAS software (SAS Institute, Cary, NC), χ2 statistics and odds
ratios (ORs) calculated using logistic regression were used to
measure the association between the ER-α A908G mutation
and clinical or other characteristics. All P values were two-
sided.
Results
Detection of the ER-α A908G mutation and other 
sequence variants
The demographic and clinical characteristics of the breast
cancer cases evaluated for the ER mutation are given in Table
1. Slightly more than half (51.1%) of the 653 cases were pre-
menopausal and 39.1% were African American. Most cases
had early American Joint Committee on Cancer stage 1 or 2
breast cancer (88.3%) and were lymph-node negative
(60.5%).
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Demographic and tumor characteristics of breast cancer cases overall and by ER-α A908G mutation status
Characteristic Total cases (N = 653) Mutation positive (N = 37) Mutation negative (N = 616) ORa 95% CI P
n (%) n (%) n (%)
Age (years)
50+ 265 (40.6) 19 (51.4) 246 (40.0) 1.00
<50 388 (59.4) 18 (48.6) 370 (60.0) 1.65 0.41–6.64 0.48
Race
White 398 (60.9) 25 (67.6) 371 (60.2) 1.00
African American 257 (39.1) 12 (32.4) 245 (39.8) 0.70 0.34–1.42 0.32
Menopausal status
Postmenopausal 317 (48.5) 22 (59.5) 295 (47.9) 1.00
Premenopausal 336 (51.5) 15 (40.5) 321 (52.1) 1.14 0.39–3.35 0.82
Stageb
I 239 (39.3) 11 (35.5) 228 (39.5) 1.00
II 298 (49.0) 16 (51.7) 282 (48.9) 1.35 0.61–3.00 0.46
III, IV 71 (11.7) 4 (12.8) 67 (11.6) 1.67 0.50–5.64 0.41
Primary tumor size
≤ 2 cm 327 (52.3) 14 (42.4) 313 (52.9) 1.00
>2 cm 298 (47.7) 19 (57.6) 279 (47.1) 1.81 0.87–3.74 0.11
Lymph node status
Negative 377 (60.5) 18 (54.5) 359 (60.8) 1.00
Positive 246 (39.5) 15 (45.5) 231 (39.2) 1.46 0.71–2.99 0.30
ER expression
ER+ 370 (58.8) 20 (58.8) 350 (58.8) 1.00
ER- 259 (41.2) 14 (41.2) 245 (41.2) 1.24 0.60–2.56 0.57
Mitotic indexc
≤ 10 364 (56.4) 25 (67.6) 339 (55.8) 1.00
>10 281 (43.6) 12 (32.4) 269 (44.2) 0.74 0.35–1.54 0.42
Histologic grade
Well to moderately 
differentiated
221 (34.1) 11 (29.7) 210 (34.3) 1.00
Poorly differentiated 428 (65.9) 26 (70.3) 402 (65.7) 1.43 0.69–2.99 0.34
Nuclear grade
Slight to moderate 
pleomorphism
375 (57.7) 20 (54.1) 355 (57.9) 1.00
Marked pleomorphism 275 (42.3) 17 (45.9) 258 (42.1) 1.48 0.74–2.97 0.27
Combined tumor graded
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invasive breast tumors. Tumor samples carrying the A908G
mutation produced a characteristic band shift on SSCP, simi-
lar to that exhibited by the positive control benign breast tis-
sue, as shown in Fig. 1a. DNA sequencing confirmed the
presence of the mutation in tumors exhibiting the variant
SSCP pattern, including tumor 52, as shown in Fig. 1b. Some
tumors showed intense mutant ER-α A908G bands on
sequencing (tumors 15, 28, 52, and 341), whereas others
showed very faint bands (tumor 313), suggesting the pres-
ence of this mutation in only a minor subpopulation of cells in
some tumor tissues. Three tumors, including tumors 52 and
341 (Fig. 1b), exhibited only the mutant base G at position
908 on sequencing, indicating that these tumors had under-
gone loss of the wild-type ER-α allele.
To confirm the somatic nature of the ER-α A908G mutation,
we sequenced germline DNA extracted from the peripheral
blood of 27 of the 37 positive CBCS cases, including all those
whose breast tumors prominently displayed the mutation,
because these cases would be most likely to carry a germline
change. The A908G base change was not detected in the
germline of any case.
In addition to carrying the A908G mutation in codon 303,
tumor 52 also exhibited a one-base deletion (of A) in codon
302, resulting in a frame shift that would be expected to pro-
duce a null ER-α protein. The two mutations probably
occurred on the same allele because only the double-mutant
sequence was observed; the wild-type sequence was absent
from this tumor (Fig. 1b). Neither mutation was detected in
corresponding germline DNA from this case. Tumor 52 was
negative for ER expression, which would be consistent with
production of only the truncated ER-α protein.
The previously reported ACG→ACA silent variant in codon
311 [16] was identified in three tumors by SSCP and
sequencing, and its presence was also confirmed by sequenc-
ing the corresponding germline DNA. All three cases carrying
the codon 311 polymorphism were African American, which is
consistent with the study of Schubert and colleagues [16],
which evaluated 105 cases and 151 controls from the CBCS.
However, the codon 311 variant did not seem to be linked with
a codon 309 (TCC→TTC) polymorphism also described in
their report, because we did not detect the codon 309 variant
in any CBCS cases by SSCP and sequencing, including
those who carried the codon 311 polymorphism.
Clinical and patient characteristics associated with the 
ER-α A908G mutation
We evaluated the association of the ER-α A908G mutation
with demographic and clinical characteristics of the breast
cancer cases. The mutation was detected in 4.5% of premen-
opausal and 6.9% of postmenopausal cases, whereas 6.3%
of white cases and 4.7% of African American cases carried
the mutation. These differences were not statistically signifi-
cant (Table 1). Cases who were older than 50 years of age
and whose tumors were later stage, of larger size, and lymph-
node positive were somewhat more likely to have mutation-
positive breast cancers, although these results were not statis-
tically significant. In particular, breast tumors having a higher
combined grade were more likely to carry the ER-α A908G
mutation (odds ratio (OR) = 2.83, 95% confidence interval
(CI) = 1.09 to 7.34 for grade II; OR = 1.65, 95% CI = 0.60 to
4.59 for grade III compared with grade I). There was a weak
positive, but not statistically significant, association between
ER-α A908G mutation status and ER protein expression in
breast tumors. However, because most ER data were
abstracted from medical records and detailed quantitative
data on the percentage tumor cells expressing ER were not
available [14], the precise relationship between ER-express-
ing cells and those carrying the mutation could not be
determined.
I 162 (25.2) 6 (16.2) 156 (25.7) 1.00
II 198 (30.7) 18 (48.7) 180 (29.7) 2.83 1.09–7.34 0.03
III 284 (44.1) 13 (35.1) 271 (44.6) 1.65 0.60–4.59 0.33
Histologic type(s)
Ductal NOSe 513 (78.6) 27 (73.0) 486 (78.9) 1.00
Ductal variantsf 21 (3.2) 1 (2.7) 20 (3.2) 0.69 0.09–5.42 0.72
Lobularg 58 (8.9) 2 (5.4) 56 (9.1) 0.57 0.13–2.50 0.46
Mixed lobular/ductal 61 (9.3) 7 (18.9) 54 (8.8) 2.10 0.86–5.12 0.10
aOdds ratios adjusted for age and race. bAccording to the American Joint Committee on Cancer breast tumor staging guidelines. cPer 10 high 
power fields. dComposite score based on mitotic index, histologic grade and nuclear grade. eDuctal NOS (not otherwise specified), n = 462; 
medullary, n = 4; neuroendocrine, n = 2; poorly differentiated, n = 13; metaplastic, n = 5; other mixed, n = 27. fDuctal variants include mucinous 
(n = 11), tubular (n = 2), papillary (n = 4), and other (n = 4). gLobular, classic and/or variant. CI, confidence interval; ER, estrogen receptor.
Table 1 (Continued)
Demographic and tumor characteristics of breast cancer cases overall and by ER-α A908G mutation status
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four groups. The prevalence of the ER-α A908G mutation was
11.5% in mixed lobular/ductal tumors, 5.3% in ductal NOS
(not otherwise specified), 4.8% in ductal variants, and 3.4% in
lobular tumors. Mixed lobular/ductal tumors were more likely
than ductal tumors to carry the ER-α A908G mutation (OR =
2.10, 95% CI = 0.86 to 5.12), although this result was not sta-
tistically significant (Table 1). It should be noted that the initial
histopathologic review of these CBCS tumors took place in
the mid-1990s; however, according to more updated his-
topathologic criteria, several of the seven mutation-positive
mixed lobular/ductal tumors would now be described as 'duc-
tal carcinoma with lobular features'. Only one ER-α A908G
mutation-positive variant lobular tumor was considered possi-
bly a pleomorphic lobular carcinoma, but information on E-cad-
herin expression was not available for this tumor to confirm this
diagnosis. The higher prevalence of the A908G mutation in
mixed lobular/ductal tumors might explain in part the stronger
association of the mutation with tumor grade II rather than
grade III, because breast tumors with a lobular component
tend to be of lower grade than non-lobular tumors.
Comparison of 33P-cycle sequencing with methods used 
in previous studies
Since the initial discovery of the ER-α A908G mutation in
breast hyperplasias [9], four studies have failed to detect this
variant in benign or malignant breast tissues [17-20]. Three of
these used fluorescent DNA sequencing [18-20] and one
used a MboII restriction digest approach [17]. To determine
whether differences in laboratory methods contributed to
these negative results, we performed several direct compari-
sons between 33P-cycle sequencing, which we used to con-
firm SSCP-positive findings in the CBCS, and fluorescent
DNA sequencing with Big Dye terminators, 35S manual DNA
sequencing, and the SNaPshot dideoxy single-base extension
method.
We selected a panel of 10 CBCS breast tumors, 8 positive
and 2 negative for the ER-α A908G mutation according to
33P-cycle sequencing (Table 2). The proportion of mutant in
the eight positive tumors ranged from about 5% to 100% of
template, on the basis of the relative intensities of mutant to
wild-type bands on 33P-cycle sequencing autoradiographs.
Fluorescent sequencing was initially performed on the 104-bp
Figure 1
SSCP and sequencing analysis of the ER-α A908G mutation in invasive breast tumors. (a) Single-strand conformational polymorphism (SSCP) 
analysis showing the band shift characteristic of the estrogen receptor-α (ER-α) A908G mutation in ductal breast tumor 52 and in the positive con-
trol tissue MN31 (Pos). Tumors 51 and 53 to 55 show the wild-type SSCP pattern, as does the MCF-7 negative control cell line (Wt). Und is the 
undenatured wild-type control. (b) 33P-Cycle sequencing analysis confirming the presence of the ER-α A908G mutation in breast tumors 52, 15, 28, 
313 and 341, as indicated by the upper arrow (A→G). Tumor 87 shows only wild-type ER-α. Note that tumor 52 also carried a second mutation, a 
deletion of A in codon 302, indicated by the lower arrow (del A), which seems to be in the allele exhibiting the A908G mutation in codon 303.
87 313 34115 2852
51 52 53 54 55 Pos Wt Und
G A T C G A T C G A T C G A T C G A T C G A T C
(a)
(b)
A>G
del A
Breast Tumors
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sequencing, but this small amplicon did not yield satisfactory
fluorescent sequencing data because of its high G/C content
and the close proximity of primers to the codon of interest.
Primers were redesigned to generate a larger 219-bp ER-α
exon 4 PCR product, which yielded good quality fluorescent
sequencing. However, all eight 33P-cycle sequencing-positive
tumors were completely negative by fluorescent sequencing,
even though cloned DNA from the positive control breast tis-
sue, which contained only mutant and no competing wild-type
sequence, did exhibit the ER-α A908G mutation by this
method. The SNaPshot method detected the mutation in
seven of the eight positive tumors, but failed to identify it in one
tumor in which it was present at less than 20% of total DNA
template. An example of the results obtained using multiple
screening methods for one ER-α A908G mutation-positive
CBCS tumor is given in Fig. 2.
For further assessment of the relative sensitivities of the meth-
ods that successfully detected the ER-α mutation, several
additional comparisons were made. 35S manual sequencing
using the Sequenase version 2.0 Sanger method was per-
formed on 20 CBCS breast tumors screened by 33P-cycle
sequencing; of these, 11 were positive and 6 negative for the
A908G mutation, and 3 were positive for the codon 311 vari-
ant. 35S manual sequencing produced the same results as
33P-cycle sequencing in all 20 samples.
The SNaPshot analysis was expanded to a total of 101 breast
tumors (including the 10 in Table 2), 33 mutation-positive and
68 mutation-negative by 33P-cycle sequencing. Of the 33
A908G-positive tumors, 27 (82%) were also positive by
SNaPshot, and these were all judged to contain more than
20% mutant template. The six SNaPshot-negative but 33P-
cycle sequencing-positive tumors were estimated to contain 5
to 20% mutant. Thus, SNaPshot generally confirmed our find-
ings with 33P-cycle sequencing when the proportion of mutant
sequence in DNA samples was above 20%. We attempted to
enhance the sensitivity of SNaPshot to detect the mutant by
first digesting ER-α exon 4 with the MboII restriction enzyme,
which cleaves only the wild-type sequence. One previous
study used this approach in combination with fluorescent
sequencing [20]. We found that digestion of ER-α exon 4 with
MboII, followed by PCR re-amplification and SNaPshot analy-
sis, led to a high frequency of false positive results for the ER-
α A908G mutation, including positive findings in cell lines that
had already been determined by 33P-cycle sequencing to con-
tain only wild-type ER-α exon 4 (results not shown).
Discussion
Our results confirm the presence of the ER-α A908G mutation
in invasive breast cancer, although the overall mutation fre-
quency is low. This finding is consistent with the literature,
which indicates that mutations of the ER-α gene occur at low
frequency in primary breast tumors [2,3]. The A908G base
change was not detected in the germline of any case; this is
consistent with the study of Fuqua and colleagues [9], which
failed to find the mutation in normal breast epithelium adjacent
to A908G mutation-positive breast hyperplasias. Schubert
and colleagues [16] also evaluated the ER-α A908G base
Table 2
Comparative results of screening methods to detect the ER-α A908G mutation
CBCS tumor 33P-cycle sequencing Fluorescent sequencing SNaPshot primer extension
28 + - +
36 + - +b
313 + - +
536 + - +
622 +a - +
684 + - +
705 + - +b
710 +a - -
162 - - -
297 - - -
Positive control tissue + - +
Mutant clone from positive control + + n.d.
aThe mutation was also confirmed by 35S manual sequencing in these samples; other tumors shown were not evaluated by this method.
bMutant peaks were small, indicating low-level positivity.
CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; n.d., not determined.
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failed to detect it in germline DNA.
Despite the initial finding of this mutation in hyperplastic breast
lesions [9] and subsequently its detection in a high proportion
of breast cancers [10], four recent studies by other research-
ers have failed to find the A908G mutation in either benign or
malignant breast tissues [17-20]. It seems likely that multiple
factors have contributed to the variable results across studies.
These include laboratory screening methods, different tumor
or patient characteristics of the populations evaluated, rela-
tively small numbers of breast tumors evaluated previously, the
apparent low prevalence of the mutation, its presence in a
minority of cells within some tumor tissues, and a histologic
Figure 2
Comparison of screening methods in one ER-α A908G mutation-positive breast tumor from the CBCS. (a) Single-strand conformational polymor-
phism analysis of three Carolina Breast Cancer Study (CBCS) breast tumors, with the mutant band in tumor 622 indicated by an arrow. Tumors 615 
and 617 contain only wild-type estrogen receptor (ER). (b) 33P-cycle sequencing showing the A908G point mutation in CBCS breast tumor 622 
(indicated by the arrow). (c) SNaPshot dideoxy primer extension analysis showing the wild-type (wt) and mutant (mut) ER peaks in both the 5' and 3' 
directions in CBCS breast tumor 622. Note that in the 5' direction the wild-type peak (A) is green and the mutant (G) is blue, whereas in the 3' direc-
tion, the wild-type peak (T) is red and the mutant (C) is black. (d) Big Dye terminator cycle sequencing analysis in the exon 4 region of ER-α sur-
rounding codon 303 in CBCS breast tumor 622. Codon 303 is boxed; note that only the wild-type sequence (AAG) is observed.
(a) (b)
(c)
(d)
616 621 622 G A T C
3' 5'
mut
mut
wt
wt
A>G
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R879preference for mixed lobular/ductal carcinomas that consti-
tuted fewer than 10% of breast tumors in the CBCS.
The previous negative studies evaluated primarily ductal carci-
nomas and included few, if any, mixed lobular/ductal carcino-
mas [17-20]. Two of the negative studies screened Japanese
breast cancer patients who may have experienced different
hormonal exposures from cases in our study [17,18]. One
recent negative study assessed a highly selected group of ER
expression-positive breast tumors from postmenopausal can-
cer patients treated with anti-estrogen therapy [20]. Our
study, in contrast, assessed a large population-based series of
more than 650 breast tumors of various histologic types from
both premenopausal and postmenopausal women.
Laboratory screening techniques might have significantly con-
tributed to the negative findings of several previous studies.
One negative study relied on restriction digestion with the
MboII restriction enzyme to detect the point mutation [17].
Detection of restriction products on agarose gels is relatively
insensitive in comparison with radiolabeling techniques,
because small amounts of undigested template, which could
correspond to mutant, might not be visible, and incomplete
digestion of wild-type template could be mistaken for mutant.
In our hands, MboII was an inefficient cutter that never
digested wild-type ER sequence to completion. This enzyme
can also exhibit star activity, or inappropriate cutting, when
digestion is allowed to proceed for more than the recom-
mended time. Incomplete or inappropriate digestion by MboII
may have contributed to background bands that we observed
in sequencing and the false positive findings we obtained with
the combination of MboII pre-digestion followed by SNaPshot.
Similar anomalies associated with use of MboII were also
reported recently by Davies and colleagues [20].
Three negative studies used automated fluorescent sequenc-
ing to screen for the A908G mutation [18-20]. Fluorescent
sequencing has been reported to be less sensitive than radi-
olabeled sequencing for detecting somatic mutations, failing
to detect one-third of mutations in the p53 gene [21]. This infe-
rior sensitivity has been attributed to unevenness in peak
heights and suppression of peaks, particularly G when it fol-
lows A, resulting in inaccuracies in base calling [22,23].
Although the use of Big Dye terminators has at least partly cor-
rected the differences in peak heights [22,23], we still
observed a fourfold to fivefold variation in peak sizes within the
ER exon 4 sequence and diminished G bases following A
bases within the codon 302 to 303 sequence (AAG-AAG)
using this method. The sensitivity of detection of the mutant G
base in codon 303 (AAG to AGG) might be particularly low
when it is present in only a small proportion of tumor cells.
Since the initial report by Fuqua and colleagues [9], we are the
only researchers to have used radiolabeled techniques to
detect the ER-α A908G mutation in breast tissues. The com-
bination of SSCP and 33P-cycle sequencing proved to be a
sensitive and reliable approach because SSCP demonstrated
a consistent band shift pattern when the mutation was
present, and even faint bands at the correct position on SSCP
gels were usually indicative of the mutation. 33P-cycle
sequencing, which permits more uniform labeling of all bases
in a sequence, clearly detected the mutation, whereas fluores-
cent sequencing did not. It should be noted that 35S
sequencing and SNaPshot dideoxy primer extension sup-
ported our findings with 33P-cycle sequencing.
The increased responsiveness of the mutant receptor to sub-
physiologic levels of estrogen, and its detection in breast
hyperplasias and now invasive carcinomas, raise the question
of its role in breast cancer etiology and prognosis. The mech-
anism of mutant hypersensitivity is not an altered affinity for
estradiol, because the mutant receptor binds hormone with
affinity similar to that of wild-type ER-α [9]. Rather, it seems to
be related primarily to an enhancement of phosphorylation at
the downstream serine 305 residue via multiple kinase signal-
ing pathways [10-12]. Thus, the mutation could function in the
early stages of neoplastic development by stimulating cellular
proliferation, increasing the formation of genetic changes
associated with breast tumorigenesis. Our finding of higher
tumor grade among the A908G mutation-positive tumors sug-
gests that upregulated and/or aberrant estrogen signaling
might be associated with the mutation and could lead to more
aggressive tumor growth. It will be of interest to determine
whether oral contraceptives, hormone replacement therapy or
other endogenous hormonal factors interact with the ER-α
A908G mutant to augment the growth of preneoplastic cells
or established tumors. From the standpoint of therapy, it will
also be important to determine whether the mutation influ-
ences response or the development of resistance to tamoxifen
or other anti-estrogen therapies. A recent report by Michalides
and colleagues [24] found that phosphorylation of serine 305
by PKA induces resistance to tamoxifen and may even convert
tamoxifen from an antagonist to an agonist, although Fuqua
and colleagues [9] did not find evidence for this in studies in
vitro.
Our data from the CBCS indicate that the ER-α A908G muta-
tion is present at a low frequency in invasive breast tumors and
may occur more frequently in higher-grade cancers. The
mutation may be associated with the mixed lobular/ductal
tumor type, a less-characterized histologic entity, although this
result was not statistically significant. Although the relationship
of the hypersensitive ER-α A908G mutation to clinical and
tumor growth characteristics is of significant interest, our
results are based on a relatively small number of mutation-pos-
itive tumors even though the CBCS is the largest series of
breast cancers yet screened for this mutation. Clearly, addi-
tional larger studies are needed to clarify the role of this mutant
in breast cancer development.
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Our results confirm the presence of the ER-α A908G muta-
tion, originally described in hyperplastic benign breast tissues,
in some invasive breast cancers. Although the frequency of
this mutation was low, it was more prevalent in subgroups of
higher-grade breast tumors and those with mixed lobular/duc-
tal histology. The presence of the hypersensitive ER-α A908G
point mutation in invasive breast tumors may have important
implications for breast cancer etiology and prognosis.
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